Clinical Trials Logo

Cognitive Impairment clinical trials

View clinical trials related to Cognitive Impairment.

Filter by:

NCT ID: NCT02300896 Active, not recruiting - Clinical trials for Cognitive Impairment

Functional and Cognitive Impairment Prevention for Elderly Hospitalized Patients

Start date: March 2015
Phase: N/A
Study type: Interventional

The current model of care for the hospitalized elderly patients has been conditioned by many factors unrelated to the disease process that caused the hospitalization and usually worsen the outcome of hospitalization circumstances. Many times hospitalized elderly patients spend most of the time in bed (even higher than 83% of bed rest versus 4% of those who stand or are walking). These patients have their functional and physiological reserve reduced which makes them more vulnerable to the effects of being bedridden. The consequences are at multiple levels emphasizing the functional loss or cognitive impairment, longer stays, mortality and institutionalization, delirium, deconditioning, pressure ulcers and decreased caloric intake, social isolation, poor quality of life and increased use of resources related to health. Exercise training can prevent functional and cognitive decline and modify even the posterior trajectory.

NCT ID: NCT02293915 Completed - Clinical trials for Cognitive Impairment

An Efficacy and Safety Study of Sodium Oligo-mannurarate (GV-971) Capsule for the Treatment of Alzheimer's Disease

Start date: April 1, 2014
Phase: Phase 3
Study type: Interventional

The primary purpose of this study is to determine the efficacy and safety of Sodium Oligo-mannurarate (GV-971) in 36-week treatment of mild to moderate Alzheimer's disease.

NCT ID: NCT02221661 Completed - Clinical trials for Cognitive Impairment

Performance of AclarusDx® a Blood-Based Transcriptomic Test for AD, in French Patients Newly Referred to a Memory Center

DIALOG
Start date: December 2011
Phase: N/A
Study type: Observational [Patient Registry]

The purpose of this study is to assess the performance of AclarusDx™, an investigational blood test detecting gene expression information, and intended to help physicians in making an Alzheimer's Disease diagnosis in patients having memory complaint and/or cognitive impairments.

NCT ID: NCT02213900 Completed - Depression Clinical Trials

Preventing Post-Operative Delirium in Patients Undergoing a Pneumonectomy, Esophagectomy or Thoracotomy

PE-POD
Start date: September 2013
Phase: Phase 4
Study type: Interventional

The purpose of this study is to investigate the effectiveness of a preventative low-dose of Haloperidol to prevent delirium in patients undergoing a esophagectomy, pneumonectomy or thoracotomy. Delirium is state of severe confusion and some symptoms include: - Cannot think clearly - Have trouble paying attention - Have a hard time understanding what is going on around them - May see or hear things that are not there. These things seem very real to them.

NCT ID: NCT02164669 Recruiting - Clinical trials for Cognitive Impairment

Exploration of Neuroimaging and Biochemical Prognostic Indicators for POCD

Start date: May 2013
Phase: N/A
Study type: Observational [Patient Registry]

Postoperative cognitive dysfunction (POCD) may lead to serious consequences. But the underlying mechanisms are still unclear. Blood Oxygen Level Dependent (BOLD) fMRI and biochemical indicators will be used to explore the underlying mechanisms and represent a promising precursory target for diagnosis and treatment of POCD.

NCT ID: NCT02145702 Terminated - Clinical trials for Cognitive Impairment

Impact of Exercise on Cognitive Impairment in End-Stage Renal Disease

Start date: May 2014
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the impact of 12 weeks of exercise on cognition in patients with end stage renal disease.

NCT ID: NCT02139410 Completed - Clinical trials for Cognitive Impairment

IGF-1, Sarcopenia and Mortality: a Cohort Study in Patient With Cognitive Impairment

ISAAC
Start date: June 2008
Phase: N/A
Study type: Observational

Insulin-like growth factor 1 (IGF)-1 is an important neuromyotrophic hormone. Disregulation of this hormone has been reported to influence the genesis of cognitive impairment and dementia in the elderly patients. We analyzed the possible link between IGF-1 and risk of Sarcopenia and Mortality in a cohort of elder patients with cognitive impairment.

NCT ID: NCT02122198 Completed - Clinical trials for Cardiovascular Disease

Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women

Start date: September 8, 2014
Phase: N/A
Study type: Interventional

Complaints about memory and thinking are common in women as they go through menopause and estrogen levels fall. The ovarian hormone estrogen is important for supporting normal cognitive function, and changes in brain activity and function occur when estrogen levels are decreased. Estrogen is also important for maintaining healthy blood vessels which also support normal cognitive function. In Alzheimer's disease and other types of dementia, there is significant damage to the blood vessels in the brain. This study will test whether changes in brain activity and function with the loss of estrogen are related to changes in vascular function. The investigators will measure vascular function using ultrasound, and brain activity using MRI scans in women who are enrolled in the Females, Aging, Metabolism and Exercise (FAME) study (NCT01712230). In the FAME study, healthy premenopausal women either take a medication to decrease their estrogen levels, or a placebo. This sub-study may provide new information about how estrogen affects vascular function and cognitive function, and lead to new ways to prevent or delay cognitive impairment or dementia.

NCT ID: NCT02099890 Completed - Depression Clinical Trials

The Effect of Diet on Chronic Inflammation and Related Disorders Following Spinal Cord Injury

Start date: September 2014
Phase: Phase 3
Study type: Interventional

Spinal cord Injury (SCI) is a condition commonly associated with a state of chronic low-grade inflammation due to a variety of factors such heightened risk for infection and development of metabolic disorders. Many disorders which have been demonstrated to have an inflammatory basis have also been found to be at much higher prevalence following SCI. Such conditions include, but are not limited to, depression, cognitive impairment, neuropathic pain, and somatic/autonomic nerve function. The fact that such disorders have an inflammatory basis provides a unique opportunity to treat them with intervention strategies which target the immune system. Natural anti-inflammatory interventions including a diet consisting of foods and supplements with anti-inflammatory properties may be an effective option for treating inflammation in this population. As this treatment strategy will target the inflammatory basis of many disorders it would be expected to lead to a reduction in pro-inflammatory mediators thereby leading to more sustainable long-term immune improvements regarding enzyme function and protein balances. Despite this, surprisingly little research has focused on the use of anti-inflammatory foods for the treatment of chronic inflammatory conditions, and effects specific to SCI have been almost completely neglected. As such, the current study will focus on the daily intake of natural supplements with anti-inflammatory properties over a 3 month intervention and the effects on inflammation and associated disorders will be assessed. It is hypothesized that the supplementation will result in positive alterations in enzyme regulation and protein balances resulting in improvements in each of the outcome measures of interest.

NCT ID: NCT02090855 Completed - Clinical trials for Cognitive Impairment.

Re-Read Study to Compare the Brain Uptake of [18F]Flutemetamol With Brain Neuritic Plaque Density Determined Postmortem

Start date: September 2013
Phase: Phase 3
Study type: Observational

Data from subjects who had previously been dosed with Flutemetamol (18F) Injection and imaged in Study GE-067-007, and who died on or before 10 June 2013, will be analyzed. The PET brain images previously obtained in Study GE-067-007 will be interpreted visually in randomized by 5 independent readers who are blinded to all other subject information, and the images will be classified as abnormal (positive for abnormal neuritic plaque density) or normal (negative for abnormal neuritic plaque density). The numbers of images in each category will be used to calculate sensitivity and specificity.